Oppenheimer Asset Management Inc. Has $7.76 Million Stock Holdings in Pfizer Inc. $PFE

Oppenheimer Asset Management Inc. trimmed its position in Pfizer Inc. (NYSE:PFE) by 1.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 319,906 shares of the biopharmaceutical company’s stock after selling 3,565 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Pfizer were worth $7,755,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of PFE. GKV Capital Management Co. Inc. acquired a new stake in Pfizer in the first quarter worth $27,000. Curio Wealth LLC raised its stake in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the period. North Capital Inc. acquired a new stake in Pfizer during the 1st quarter worth $28,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the first quarter worth about $28,000. Finally, Harbor Asset Planning Inc. acquired a new stake in shares of Pfizer during the second quarter worth about $29,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PFE has been the topic of a number of research analyst reports. UBS Group reaffirmed a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Morgan Stanley dropped their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Bank of America lifted their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $28.13.

Pfizer Stock Down 0.0%

Shares of PFE opened at $24.76 on Tuesday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.17. The firm’s 50-day simple moving average is $24.86 and its 200 day simple moving average is $24.21. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market cap of $140.75 billion, a P/E ratio of 13.17, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the firm posted $0.60 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.